| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1031120077 |
| P356 | DOI | 10.1186/1471-2407-10-667 |
| P932 | PMC publication ID | 3016292 |
| P698 | PubMed publication ID | 21129184 |
| P5875 | ResearchGate publication ID | 49655993 |
| P50 | author | Noboru Nakaigawa | Q87997874 |
| P2093 | author name string | Takeshi Miura | |
| Tomio Inoue | |||
| Yoshinobu Kubota | |||
| Takeshi Kishida | |||
| Kazuki Kobayashi | |||
| Futoshi Sano | |||
| Kazuhide Makiyama | |||
| Kazuhiro Namura | |||
| Masahiro Yao | |||
| Narihiko Hayashi | |||
| Ukihide Tateishi | |||
| Ryogo Minamimoto | |||
| Takayuki Murakami | |||
| Sumio Noguchi | |||
| Hanako Ishigaki | |||
| P2860 | cites work | Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 |
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. | Q33880227 | ||
| Renal-cell carcinoma | Q34394356 | ||
| Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer | Q34536176 | ||
| Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma | Q34553839 | ||
| Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial | Q34583699 | ||
| Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease | Q35609578 | ||
| Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma | Q35742970 | ||
| Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. | Q35862872 | ||
| Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute | Q40893119 | ||
| Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients | Q44288753 | ||
| Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. | Q44502912 | ||
| F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma | Q44633987 | ||
| Impact of immune parameters on long-term survival in metastatic renal cell carcinoma | Q44811646 | ||
| Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose | Q44994021 | ||
| [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer | Q45271717 | ||
| The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. | Q45928506 | ||
| Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. | Q45971555 | ||
| 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study | Q46109198 | ||
| Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma | Q46248290 | ||
| Rising incidence of renal cell cancer in the United States | Q46854143 | ||
| Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie | Q74486208 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | computed tomography | Q32566 |
| renal cell carcinoma | Q1164529 | ||
| Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography | Q130273251 | ||
| tomography | Q841267 | ||
| P304 | page(s) | 667 | |
| P577 | publication date | 2010-12-03 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report | |
| P478 | volume | 10 |
| Q89702915 | A large bi-lobed classic renal angiomyolipoma with vena caval extension |
| Q37014111 | Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. |
| Q42363905 | Assessment of cell proliferation in renal cell carcinoma using dual-phase (18)F-fluorodeoxyglucose PET/CT |
| Q33639383 | Can Initial (18)F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma? |
| Q35169825 | Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer |
| Q52877176 | Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study. |
| Q34253776 | Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course |
| Q64083369 | Early assessment with F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab |
| Q33755947 | Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study |
| Q36662636 | FDG PET or PET/CT in evaluation of renal angiomyolipoma |
| Q35917780 | FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma |
| Q93384702 | FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma |
| Q36567385 | Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma |
| Q34990800 | Management of urological malignancies: Has positron emission tomography/computed tomography made a difference? |
| Q35915703 | Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications |
| Q38837758 | Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies |
| Q37550399 | Molecular imaging of urogenital diseases |
| Q47094599 | Oncocytoma: A Differential Consideration for an Incidentally Detected FDG-Avid Renal Mass on PET/CT. |
| Q52780316 | One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival. |
| Q49165684 | PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art. |
| Q37711287 | Positron emission tomography/computed tomography imaging features of renal cell carcinoma and pulmonary metastases in a dog. |
| Q36001780 | Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma |
| Q92358587 | Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma |
| Q38196855 | Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents |
| Q45823946 | Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy |
| Q61810791 | Synchronous bilateral renal cell carcinomas in "Asynchrony of metabolism" |
| Q28070239 | The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations |
| Q37576212 | The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy |
| Q33792683 | The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ |
| Q34569318 | The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer |
| Q41660750 | Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. |
| Q33625389 | Update on advances in molecular PET in urological oncology |
| Q85461968 | [Positron-emission tomography in urooncology] |
Search more.